ALS INVESTMENT FUND

We are a Venture Capital fund that invests in biotech companies developing drugs in a specialized area of disease: neurodegeneration, with a particular focus in ALS.

Neurodegenerative diseases are one of the main health challenges of humankind

We all want to live longer with sound minds and strong bodies. In order to do this we must tackle the challenge of chronic diseases that destroy the neurons controlling our minds, muscles, and other areas of the body. Alzheimer’s disease, Parkinson’s disease, and ALS all result from this fundamental problem of dying neurons.

INVESTMENT PHILOSOPHY

We invest in biotech companies with balanced teams applying cutting edge technologies. We look for companies with either platform approaches relevant to multiple diseases, and/or with multiple drugs already in clinical development. The companies in our portfolio have already proven the basic science behind their approaches and are working towards a value inflection point.

Read more about the profile of our investments here and our portfolio here.

“To date we are managing the biggest most diversified portfolio of ALS related companies worldwide.”

NICHE INVESTMENT WITH A BROAD REACH

We are a highly specialized biotech investor. We currently manage the largest and most diversified portfolio of ALS related companies worldwide. We are also globally among the most diversified VC funds in neurodegeneration in general with the ambition to build out this position. The knowledge we gather through our portfolio and our longstanding relationships with a global ALS-related network of scientists, clinicians, foundations, and patient advocates, differentiates us from other investors. Read more.

"By specialization a disease focused VC Fund offers unique added value to investors, portfolio companies and ultimately to patients"

TEAM

Our mission is to advance companies developing treatments for neurodegenerative disease and ALS in particular. Our commitment to this mission is fueled by personal ties to ALS. Never losing sight of this mission, we have joined our complementary skills and years of experience together in order to successfully bring novel drugs and technologies to the market and make a return for our investors (social impact as well as financial return). Our scientific advisory board is comprised of internationally renowned key opinion leaders. Read here

The ALS Investment Fund is managed by SUNU Ventures BV, a Dutch limited company